In my view, the next big announcement shall be a big pharma partner for COVID-19. The last 4C put the discussions ongoing for at least a month. During the last conf call, the CFO refused to get drawn into a discussion or answer the analyst question on funds allocated for manufacturing in next quarters. Maybe the last fresh equity funds raise put the company in a better negotiation position, but won’t actually be needed for manufacturing if there is a big pharmaceutical partnership....
Here is an excerpt from MESOBLAST’s last 4C: “Mesoblast is in active discussions with US and other government authorities as well as potential pharmaceutical partners with respect to its plans for ramp-up of commercial manufacturing for remestemcel-L in COVID-19 ARDS.”
http://investorsmedia.mesoblast.com/static-files/04851ade-aca5-492c-9784-45ae8c772f04
- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-144
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.15 |
Change
0.065(5.99%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.12 | $1.20 | $1.11 | $20.08M | 17.25M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 533 | $1.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 24215 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 86342 | 1.145 |
10 | 129699 | 1.140 |
8 | 83353 | 1.135 |
14 | 204225 | 1.130 |
6 | 41120 | 1.125 |
Price($) | Vol. | No. |
---|---|---|
1.150 | 46346 | 6 |
1.155 | 112439 | 9 |
1.160 | 309881 | 12 |
1.165 | 216768 | 10 |
1.170 | 63449 | 7 |
Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.15 |
  |
Change
0.065 ( 5.63 %) |
|||
Open | High | Low | Volume | ||
$1.12 | $1.20 | $1.12 | 3730649 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online